Arbutus Biopharma (ABUS) Times Interest Earned (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Times Interest Earned of $7343.8 for Q1 2026, up 900.14% year-on-year from $734.28 in Q1 2025, and up 77147.7% on a QoQ basis from -$9.53 in Q4 2025.
Arbutus Biopharma (ABUS) Times Interest Earned (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Times Interest Earned for 14 consecutive years, with $7343.8 the latest figure, recorded in Q1 2026.
- Quarterly Times Interest Earned rose 900.14% year-over-year to $7343.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6802.0 (up 1178.06% YoY) and the FY2025 annual result came in at -$0.21, up 51.64% from the prior year.
- Times Interest Earned rose to $7343.8 in Q1 2026 per ABUS's latest filing, from -$9.53 in the prior quarter.
- Over the last five years, Times Interest Earned for ABUS reached as high as $7343.8 in Q1 2026 and fell as low as -$917.82 in Q1 2025.
- A 5-year average of $197.21 and a median of -$107.51 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned slumped 1721.76% — and 2026, when it jumped 900.14%.
- Year by year, Times Interest Earned stood at $29.07 in 2022, then sank by 1721.76% to -$471.52 in 2023, then climbed by 1.5% to -$464.43 in 2024, then jumped by 97.95% to -$9.53 in 2025, then jumped by 77147.7% to $7343.8 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $7343.8, -$9.53, and -$376.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 7,343.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,343.83 |
| Dec 31, 2025 | -9.53 |
| Sep 30, 2025 | -376.48 |
| Jun 30, 2025 | 53.14 |
| Mar 31, 2025 | -917.82 |
| Dec 31, 2024 | -464.43 |
| Sep 30, 2024 | -739.31 |
| Jun 30, 2024 | -222.51 |
| Mar 31, 2024 | -115.26 |
| Dec 31, 2023 | -471.52 |
| Sep 30, 2023 | -468.65 |
| Jun 30, 2023 | -107.51 |
| Mar 31, 2023 | -87.94 |
| Dec 31, 2022 | 29.07 |
| Sep 30, 2022 | -41.52 |
| Jun 30, 2022 | -29.27 |
| Mar 31, 2022 | -21.69 |
| Dec 31, 2021 | 12.63 |
| Sep 30, 2021 | -24.16 |
| Jun 30, 2021 | -24.43 |